Postpartum Co-Prescribing Study Measured Overlapping Fills, Not Confirmed Simultaneous Ingestion

Population dispensing overlap is a risk marker rather than direct observation of combined drug use.

What the publication shows

The study examined 514,120 privately insured postpartum women. About 1.2% had concurrent opioid and benzodiazepine fills, while roughly half of women with a benzodiazepine fill also had an opioid overlap. Concurrent-fill counts increased relative to the preexisting trend in the early pandemic period.

Limits of the evidence

Claims do not establish whether each prescription was taken or whether doses overlapped at the same hour. The insured population and six-month postpartum window constrain generalization. The study measured prescribing patterns, not a new causal estimate of overdose attributable to each overlap.

Application to expert review

For an individual case, reconstruct dispensing, instructions, remaining tablets, actual administration and symptoms. Keep the denominator of all postpartum women distinct from benzodiazepine recipients. A concurrent fill supports further inquiry without proving intoxication or respiratory compromise.

Source and related reading

Source: Publication PMC11279250. The case-review applications above are interpretive analysis.